Pictet Asset Management
PCVX icon

Pictet Asset Management’s Vaxcyte PCVX Stock Holding History

Pictet Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.4M Sell
694,719
-5,592
-0.8% -$304K 0.04% 379
2026
Q1 		$40.7M Sell
700,311
-181,124
-21% -$9.83M 0.04% 353
2025
Q4 		$40.7M Sell
881,435
-148,194
-14% -$6.63M 0.04% 364
2025
Q3 		$37.1M Sell
1,029,629
-146,032
-12% -$4.84M 0.04% 379
2025
Q2 		$38.2M Buy
1,175,661
+124,983
+12% +$4.1M 0.04% 363
2025
Q1 		$42.2M Buy
1,050,678
+32,833
+3% +$2.63M 0.05% 341
2024
Q4 		$83.3M Buy
1,017,845
+236,940
+30% +$23.5M 0.09% 229
2024
Q3 		$89.2M Buy
780,905
+248,001
+47% +$22.4M 0.1% 212
2024
Q2 		$40.2M Sell
532,904
-328,665
-38% -$22.4M 0.05% 321
2024
Q1 		$58.9M Sell
861,569
-287,640
-25% -$19.9M 0.06% 281
2023
Q4 		$72.2M Sell
1,149,209
-325,573
-22% -$16.9M 0.08% 248
2023
Q3 		$75.2M Buy
+1,474,782
New +$72.8M 0.09% 226

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Pictet Asset Management's PCVX Position: Q2 2026 in Review

Pictet Asset Management reduced its Vaxcyte (PCVX) stake by 0.8% in Q2 2026, selling an estimated $304K and leaving 694,719 shares worth $40.4M. The position accounts for 0.04% of the portfolio, ranked #379.

Pictet Asset Management first reported a position in PCVX in Q3 2023 and has held it in 12 quarters since. The position peaked at $89.2M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Pictet Asset Management held 694,719 shares of Vaxcyte worth $40.4M as of Q2 2026.
  • Pictet Asset Management sold 5,592 Vaxcyte shares in Q2 2026, an estimated $304K.
  • Vaxcyte made up 0.04% of Pictet Asset Management's portfolio in Q2 2026, its #379 holding.
  • Pictet Asset Management first reported a position in Vaxcyte in Q3 2023 and has held it in 12 quarters since.
  • Pictet Asset Management's Vaxcyte position peaked at $89.2M in Q3 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.